Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
Vaccine
; 24(9): 1238-41, 2006 Feb 27.
Article
em En
| MEDLINE
| ID: mdl-16213632
ABSTRACT
We conducted a Phase 1b study to evaluate the immunogenicity and safety of two live attenuated tetravalent dengue vaccines in healthy adult volunteers. After one injection, all subjects reported systemic reactions consistent with a mild dengue-like syndrome. Seven volunteers developed dengue 3 viraemia after vaccination. All subjects developed a neutralizing antibody response against serotype 3 with partial response against other serotypes. The trial was stopped early (after 10 subjects enrolled) due to formulation issues, which were related to the dengue 3 vaccine component. Managing viral interference and balancing attenuation to produce acceptable tetravalent immunogenicity with minimal reactogenicity may be a recurring problem for future multivalent live vaccines.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vacinas Virais
/
Dengue
/
Vírus da Dengue
Limite:
Adult
/
Humans
/
Male
País/Região como assunto:
Oceania
Idioma:
En
Revista:
Vaccine
Ano de publicação:
2006
Tipo de documento:
Article
País de afiliação:
Austrália